Language:

Targeting Src in breast cancer

Annals of oncology, 2008-08, Vol.19 (8), p.1379-1386 [Peer Reviewed Journal]

2008 European Society for Medical Oncology ;The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org 2008 ;2008 INIST-CNRS ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdn291 ;PMID: 18487549

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Targeting Src in breast cancer
Author: Finn, R.S.
Subjects: Animals ; Antineoplastic agents ; Biological and medical sciences ; breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - enzymology ; Breast Neoplasms - pathology ; cancer drug development ; growth factors and receptors ; Gynecology. Andrology. Obstetrics ; Humans ; Mammary gland diseases ; Medical sciences ; oncology—metastasis ; Pharmacology. Drug treatments ; Protein Kinase Inhibitors - chemistry ; Protein Kinase Inhibitors - pharmacology ; Protein Kinase Inhibitors - therapeutic use ; Src ; src-Family Kinases - antagonists & inhibitors ; src-Family Kinases - chemistry ; src-Family Kinases - metabolism ; Structure-Activity Relationship ; translational oncology—signal transduction ; Tumors
Is Part Of: Annals of oncology, 2008-08, Vol.19 (8), p.1379-1386
Description: The clinical benefit of blocking oncogenic pathways in breast cancer and other malignancies has validated this approach and ushered in the era of molecularly targeted therapeutics. Src and its family members make up the largest group of nonreceptor tyrosine kinases. In laboratory models, these proteins have been shown to play a critical role in cellular growth and proliferation, angiogenesis, and invasion and metastasis. In addition, Src plays an important role in osteoclast activation and bone resorption, which are often aberrantly activated in the setting of bone metastases. Given its role in these functions, blocking Src kinase would be predicted to have a broad therapeutic benefit in patients with Src-dependent cancers. In this review, we highlight the rationale for targeting Src in breast cancer, including laboratory and clinical data implicating it in these signaling pathways, and review small-molecule tyrosine kinase inhibitors currently in clinical development. Identifying which patients should be selected for Src-directed therapies will be important to the clinical success of these agents. Importantly, recent preclinical data support a role for this class of inhibitors in basal-type/triple-negative breast cancer, which represents a group of patients with limited effective treatment options.
Publisher: Oxford: Elsevier Ltd
Language: English
Identifier: ISSN: 0923-7534
EISSN: 1569-8041
DOI: 10.1093/annonc/mdn291
PMID: 18487549
Source: Geneva Foundation Free Medical Journals at publisher websites
MEDLINE
Alma/SFX Local Collection

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Targeting Src in breast cancer

Searching Remote Databases, Please Wait